The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity-Reference-Cited by-同舟云学术

The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Published:2016-07-29 Issue:7 Volume:8 Page:1361-1370
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Tóth Gábor¹,Szöőr Árpád¹,Simon László¹,Yarden Yosef²,Szöllősi János¹³,Vereb György¹³⁴

Affiliation:

1. Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

2. Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel

3. MTA-DE Cell Biology and Signaling Research Group, Faculty of Medicine

4. Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://tandfonline.com/doi/pdf/10.1080/19420862.2016.1204503

Reference39 articles.

1. HER2 as a Predictor of Therapeutic Response in Breast Cancer

2. HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer Tissues

3. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab

4. ErbB-directed immunotherapy: Antibodies in current practice and promising new agents

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. Disrupting EGFR–HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome;International Journal of Molecular Sciences;2024-05-29

3. Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery;Journal of Visualized Experiments;2024-04-26

4. Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade;npj Breast Cancer;2024-04-18

5. Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development;Molecular Aspects of Medicine;2024-02